Oseltamivir
- Generic Name
- Oseltamivir
- Brand Names
- Ebilfumin, Tamiflu
- Drug Type
- Small Molecule
- Chemical Formula
- C16H28N2O4
- CAS Number
- 196618-13-0
- Unique Ingredient Identifier
- 20O93L6F9H
- Background
Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...
- Indication
According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...
- Associated Conditions
- Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B
- Associated Therapies
- -
A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Nanjing Zenshine Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT06057103
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 162
- Registration Number
- NCT05818124
- Locations
- 🇬🇧
hVIVO Services ( Site 0001), London, London, City Of, United Kingdom
A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05789342
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3000
- Registration Number
- NCT05648448
- Locations
- 🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Lao People's Democratic Republic
🇳🇵Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 2
- Registration Number
- NCT05170009
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT05108051
- Locations
- 🇨🇳
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Insight Therapeutics, LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT05012189
- Locations
- 🇺🇸
Insight Therapeutics, LLC, Norfolk, Virginia, United States
The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 388
- Registration Number
- NCT05008679
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04712539
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
IMU-838 and Oseltamivir in the Treatment of COVID-19
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2023-08-22
- Target Recruit Count
- 38
- Registration Number
- NCT04516915
- Locations
- 🇬🇧
University Hospital Coventry and Warwickshire NHS Trust, Coventry, West Midlands, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.